Regulation of insulin-like growth factor signaling by metformin in endometrial cancer cells

Oncology Letters

Volumn 8, Issue 5, 2014, Pages 1993-1999

  Xie, Y ^a   Wang, Jing Lu ^a   Ji, Mei ^a   Yuan, Zhong Fu ^a   Peng, Zheng ^a   Zhang, Y ^a   Wen, Jian Guo ^a   Shi, Hui Rong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Apoptosis; Cell proliferation; Endometrial cancer; Insulin like growth factor system; Metformin

Indexed keywords

ADENOSINE PHOSPHATE; BROXURIDINE; MESSENGER RNA; METFORMIN; PROTEIN KINASE INHIBITOR; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C RECEPTOR;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; DOWN REGULATION; ENDOMETRIUM CANCER; HUMAN; HUMAN CELL; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

EID: 84907145784     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2466     Document Type: Article

References (40)

1. Kitchener H: Management of endometrial cancer. Eur J Surg Oncol 32: 838-843, 2006.
2. Chia VM, Newcomb PA, Trentham-Dietz A and Hampton JM: Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosis. Int J Gynecol Cancer 17: 441-446, 2007.
3. Calle EE, Rodriguez C, Walker-Thurmond K and Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348: 1625-1638, 2003.
4. Steiner E, Plata K, Interthal C, et al: Diabetes mellitus is a multivariate independent prognostic factor in endometrial carcinoma: a clinicopathologic study on 313 patients. Eur J Gynaecol Oncol 28: 95-97, 2007.
5. Augustin LS, Dal Maso L, Franceschi S, et al: Association between components of the insulin-like growth factor system and endometrial cancer risk. Oncology 67: 54-59, 2004.
6. Schernhammer ES, Holly JM, Hunter DJ, Pollak MN and Hankinson SE: Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 13: 583-592, 2006.
7. Roy RN, Gerulath AH, Cecutti A and Bhavnani BR: Discordant expression of insulin-like growth factors and their receptor messenger ribonucleic acids in endometrial carcinomas relative to normal endometrium. Mol Cell Endocrinol 153: 19-27, 1999.
8. LeRoith D, Werner H, Beitner-Johnson D and Roberts CT Jr: Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16: 143-163, 1995.
9. Baserga R, Hongo A, Rubini M, Prisco M and Valentinis B: The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1332: F105-F126, 1997.
10. Werner H: The molecular basis of IGF-I receptor gene expression in human cancer. In: Insulin-Like Growth Factors. LeRoith D, Zumkeller W and Baxter RC (eds). Landes Bioscience, Austin, TX, pp346-356, 2003.
11. Navarro M and Baserga R: Limited redundancy of survival signals from the type 1 insulin-like growth factor receptor. Endocrinology 142: 1073-1081, 2001.
12. Rutanen EM: Insulin-like growth factors in endometrial function. Gynecol Endocrinol 12: 399-406, 1998.
13. Oh JC, Wu W, Tortolero-Luna G, et al: Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 13: 748-752, 2004.
14. Pavelić J, Radaković B and Pavelić K: Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma. Gynecol Oncol 105: 727-735, 2007.
15. McCampbell AS, Broaddus RR, Loose DS and Davies PJ: Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res 12: 6373-6378, 2006.
16. Pengchong H and Tao H: Expression of IGF-1R, VEGF-C and D2-40 and their correlation with lymph node metastasis in endometrial adenocarcinoma. Eur J Gynaecol Oncol 32: 660-664, 2011.
17. Werner H and Bruchim I: The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem 115: 58-71, 2009.
18. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA and Bae-Jump VL: Metformin is a potent inhibitor of endometrial cancer cell proliferation - implications for a novel treatment strategy. Gynecol Oncol 116: 92-98, 2010.
19. Rocha GZ, Dias MM, Ropelle ER, et al: Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res 17: 3993-4005, 2011.
20. Xie Y, Wang YL, Yu L, et al: Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol 126: 113-120, 2011.
21. Parazzini F, La Vecchia C, Negri E, et al: Diabetes and endometrial cancer: an Italian case-control study. Int J Cancer 81: 539-542, 1999.
22. Grady D and Ernster VL: Endometrial cancer. In: Cancer Epidemiology and Prevention. Schottenfeld D and Fraumeni JF (eds). 2nd edition. Oxford University Press, Oxford, pp1058-1089, 1996.
23. Ouban A, Muraca P, Yeatman T and Coppola D: Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 34: 803-808, 2003.
24. Petridou E, Koukoulomatis P, Alexe DM, Voulgaris Z, Spanos E and Trichopoulos D: Endometrial cancer and the IGF system: a case-control study in Greece. Oncology 64: 341-345, 2003.
25. Chen TW, Liang YN, Feng D, et al: Metformin inhibits proliferation and promotes apoptosis of HER2 positive breast cancer cells by downregulating HSP90. J BUON 18: 51-56, 2013.
26. Quentin T, Steinmetz M, Poppe A and Thoms S: Metformin differentially activates ER stress signaling pathways without inducing apoptosis. Dis Model Mech 5: 259-269, 2012.
27. Olmos D, Martins AS, Jones RL, Alam S, Scurr M and Judson IR: Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations. Sarcoma 2011: 402508, 2011.
28. Gualberto A, Hixon ML, Karp DD, et al: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 104: 68-74, 2011.
29. de Bono JS, Attard G, Adjei A, et al: Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 13: 3611-3616, 2007.
30. Dowling RJ, Zakikhani M, Fantus IG, Pollak M and Sonenberg N: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67: 10804-10812, 2007.
31. Shell SA, Lyass L, Trusk PB, Pry KJ, Wappel RL and Bacus SS: Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells. Cell Cycle 7: 1769-1775, 2008.
32. Vazquez-Martin A, Oliveras-Ferraros C, del Barco S, Martin-Castillo B and Menendez JA: The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. Ann Oncol 20: 592-595, 2009.
33. Vazquez-Martin A, Oliveras-Ferraros C and Menendez JA: The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 8: 88-96, 2009.
34. Alimova IN, Liu B, Fan Z, et al: Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8: 909-915, 2009.
35. Liu B, Fan Z, Edgerton SM, et al: Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8: 2031-2040, 2009.
36. Hadad SM, Fleming S and Thompson AM: Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol 67: 1-7, 2008.
37. Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A and Decensi A: Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev 18: 701-705, 2009.
38. Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928, 2008.
39. Carracedo A, Baselga J and Pandolfi PP: Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle 7: 3805-3809, 2008.
40. Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B and Menendez JA: If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials. J Clin Oncol 27: e207-e209, 2009.